FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4207002617> ?p ?o ?g. }

• W4207002617 endingPage "10" @default.
• W4207002617 startingPage "10" @default.
• W4207002617 abstract "Oocyte donation has become an increasingly prevalent and successful mechanism for achieving pregnancy in women of advanced reproductive age experiencing a decline in oocyte quantity and quality. The logistics of planning oocyte donation cycles can be difficult, particularly when donors are traveling from a distance or when synchronization with a recipient’s cycle is necessary for a fresh embryo transfer. Cycle programming with combined hormonal contraceptive pills has been used to overcome this challenge; however, combined hormonal contraception has been associated with longer stimulations and higher gonadotropin dose requirements (1Griesinger G. Kolibianakis E.M. Venetis C. Diedrich K. Tarlatzis B. Oral contraceptive pretreatment significantly reduces ongoing pregnancy likelihood in gonadotropin-releasing hormone antagonist cycles: an updated meta-analysis.Fertil Steril. 2010; 94: 2382-2384Google Scholar). Banker et al. (2Banker M. Arora P. Banker J. Gupta R. Shah S. Follicular phase cycle programming using estradiol in oocyte donors—a convenient and effective approach.F S Rep. 2022; 3: 20-25Google Scholar) set out to provide a second option for cycle programming in oocyte donation cycles using oral estradiol to program the start of a donor stimulation cycle in the follicular phase. In this study, they demonstrated that 8-mg estradiol hemihydrate (comparable with micronized estradiol) initiated on the second day of a menstrual cycle and continued for 2–10 days with gonadotropin initiation 1 day after the final dose of estradiol was associated with clinical outcomes similar to the same donor’s previous unprogrammed donation cycle. Notably, the investigators studied 8-mg estradiol hemihydrate, raising the question of relative ovarian suppression achieved compared with the 30-μg ethinyl estradiol in a standard combined hormonal contraceptive pill. In a prior study, oral contraceptive pills were found to result in suppressed follicle-stimulating hormone levels for up to 5 days after discontinuation, whereas a 4-mg daily dose of estradiol before treatment in the luteal phase resulted in poorly suppressed follicle-stimulating hormone on the day after discontinuation, with maximal follicle-stimulating hormone rebound 3 days after discontinuation (3Cédrin-Durnerin I. Bständig B. Parneix I. Bied-Damon V. Avril C. Decanter C. et al.Effects of oral contraceptive, synthetic progestogen or natural estrogen pretreatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol.Hum Reprod. 2007; 22: 109-116Google Scholar). In the study by Banker et al. (2Banker M. Arora P. Banker J. Gupta R. Shah S. Follicular phase cycle programming using estradiol in oocyte donors—a convenient and effective approach.F S Rep. 2022; 3: 20-25Google Scholar), the stimulation was initiated 1 day after the last estradiol hemihydrate dose, whereas stimulation is generally initiated 4–5 days after the last combined hormonal contraceptive pill. Although one might hypothesize that the recent daily dose of 8-mg estradiol hemihydrate might result in undue ovarian suppression, prolonging stimulation, and total gonadotropin requirement, the investigators did not find a statistically significant increase in gonadotropin dose or in the days of stimulation compared with the donors’ unprogrammed historical control cycle. Although the investigators demonstrate an increased mature oocyte yield with estradiol before treatment, there was no difference in maturation, fertilization, blastulation, implantation, or pregnancy rates compared with that in the unprogrammed cycles. Additionally, the total number of available blastocysts was not different from the control cycle. As a result, the investigators conclude that high-dose estradiol can be employed from the follicular phase in a similar fashion to combined hormonal contraception with similar clinical outcomes to an unprogrammed cycle. The investigators suggest that estradiol may be used for a shorter duration than combined hormonal contraception (2–10 days in this study) and, therefore, be associated with improved compliance. Compliance was not, however, assessed, and the comparator group was the donor’s index cycle without hormonal pretreatment rather than combined hormonal contraceptive pretreatment. It may be worthwhile to pursue a prospective randomized trial to identify any difference in outcomes between follicular estradiol and combined hormonal contraception administered for a similar duration, particularly if this protocol is to be introduced in the greater population of patients with infertility beyond the good prognosis group of oocyte donors. Although oral contraceptive pills may continue to be the most commonly selected method for programming oocyte donation cycles, it is helpful to have alternatives. The combined hormonal contraceptive ring has been used in a similar fashion with acceptable outcomes—and, although not studied, may be associated with higher compliance due to the avoidance of the need for daily medication (4Thomas R.L. Halvorson L.M. Carr B.R. Doody K.M. Doody K.J. Efficacy of combined contraceptive vaginal ring versus oral contraceptive pills in achieving hypothalamic-pituitary-ovarian axis suppression in egg donor in vitro fertilization cycles.J Reprod Infertil. 2013; 14: 207-213Google Scholar). Additionally, it is common to find patients who have a history of side effects from combined hormonal contraceptives that may be attributed to the progestin component. An estradiol-only approach to program cycles may put these patients at ease and promote individualization of care. Follicular phase cycle programming using estradiol in oocyte donors–a convenient and effective approachF&S ReportsVol. 3Issue 1PreviewTo study the efficacy of estradiol for cycle programming in oocyte donors when administered in the follicular phase only. Full-Text PDF Open Access" @default.
• W4207002617 created "2022-01-26" @default.
• W4207002617 creator A5038089382 @default.
• W4207002617 date "2022-03-01" @default.
• W4207002617 modified "2023-10-07" @default.
• W4207002617 title "Another option for cycle programming: follicular start estradiol in oocyte donation cycles" @default.
• W4207002617 cites W2017127513 @default.
• W4207002617 cites W2097742646 @default.
• W4207002617 cites W2117212359 @default.
• W4207002617 doi "https://doi.org/10.1016/j.xfre.2022.01.003" @default.
• W4207002617 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35386505" @default.
• W4207002617 hasPublicationYear "2022" @default.
• W4207002617 type Work @default.
• W4207002617 citedByCount "0" @default.
• W4207002617 crossrefType "journal-article" @default.
• W4207002617 hasAuthorship W4207002617A5038089382 @default.
• W4207002617 hasBestOaLocation W42070026171 @default.
• W4207002617 hasConcept C134018914 @default.
• W4207002617 hasConcept C160099875 @default.
• W4207002617 hasConcept C16685009 @default.
• W4207002617 hasConcept C187785154 @default.
• W4207002617 hasConcept C196843134 @default.
• W4207002617 hasConcept C2776690073 @default.
• W4207002617 hasConcept C2778782382 @default.
• W4207002617 hasConcept C2779058012 @default.
• W4207002617 hasConcept C2779234561 @default.
• W4207002617 hasConcept C29456083 @default.
• W4207002617 hasConcept C3018046586 @default.
• W4207002617 hasConcept C54355233 @default.
• W4207002617 hasConcept C71315377 @default.
• W4207002617 hasConcept C71924100 @default.
• W4207002617 hasConcept C86803240 @default.
• W4207002617 hasConceptScore W4207002617C134018914 @default.
• W4207002617 hasConceptScore W4207002617C160099875 @default.
• W4207002617 hasConceptScore W4207002617C16685009 @default.
• W4207002617 hasConceptScore W4207002617C187785154 @default.
• W4207002617 hasConceptScore W4207002617C196843134 @default.
• W4207002617 hasConceptScore W4207002617C2776690073 @default.
• W4207002617 hasConceptScore W4207002617C2778782382 @default.
• W4207002617 hasConceptScore W4207002617C2779058012 @default.
• W4207002617 hasConceptScore W4207002617C2779234561 @default.
• W4207002617 hasConceptScore W4207002617C29456083 @default.
• W4207002617 hasConceptScore W4207002617C3018046586 @default.
• W4207002617 hasConceptScore W4207002617C54355233 @default.
• W4207002617 hasConceptScore W4207002617C71315377 @default.
• W4207002617 hasConceptScore W4207002617C71924100 @default.
• W4207002617 hasConceptScore W4207002617C86803240 @default.
• W4207002617 hasIssue "1" @default.
• W4207002617 hasLocation W42070026171 @default.
• W4207002617 hasLocation W42070026172 @default.
• W4207002617 hasLocation W42070026173 @default.
• W4207002617 hasLocation W42070026174 @default.
• W4207002617 hasOpenAccess W4207002617 @default.
• W4207002617 hasPrimaryLocation W42070026171 @default.
• W4207002617 hasRelatedWork W1966941058 @default.
• W4207002617 hasRelatedWork W2032151890 @default.
• W4207002617 hasRelatedWork W2093148264 @default.
• W4207002617 hasRelatedWork W2155343269 @default.
• W4207002617 hasRelatedWork W2172116462 @default.
• W4207002617 hasRelatedWork W2409473644 @default.
• W4207002617 hasRelatedWork W2432310895 @default.
• W4207002617 hasRelatedWork W2784477170 @default.
• W4207002617 hasRelatedWork W3202490182 @default.
• W4207002617 hasRelatedWork W4237160041 @default.
• W4207002617 hasVolume "3" @default.
• W4207002617 isParatext "false" @default.
• W4207002617 isRetracted "false" @default.
• W4207002617 workType "article" @default.